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Abstract 
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by elevated immu-
noglobulin E (IgE), mast cell infiltration and skin lesions including pruritus, erythema and eczema. 
Cudrania tricuspidata extracts have been clinically administered for a long time in the East Asia 
including Korean and China as a home-remedy to diminish the inflammation of gastritis and hepa-
titis. To examine whether it works on AD or not, an AD-like animal model was experimented in 
this study. AD was induced by applying Dermatophagoides farinae (D. farinae) extract to the backs 
of 9-week old NC/Nga mice for 21 days. Following this, an ethanol extract of C. tricuspidata stems 
(EECT) was applied topically for 14 days to the sensitized skin, while distilled water was used as a 
control (EECT0 mice). Anti-AD effects of EECT were evaluated using scores for AD-like skin lesions, 
serum IgE levels and mast cell counts in the skin dermal layers to assess inflammation. Topically 
applied ethanol extract of Cudrania tricuspidata stems (EECT 7.5, 25 and 75 mg/mL) markedly 
reduced AD-like skin lesions after 4 days (by 30.1%, 31.4% and 38.5%, respectively) and also after 
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14 days (by 63.6%, 66.1% and 49.6%, respectively), while distilled water improved AD by 17.8% 
and 38.7%, respectively (p < 0.05). Serum IgE production was reduced in the EECT7.5, EECT25 and 
EECT75 groups after 4 days (by 57.6%, 65.9% and 59.3%, respectively) and after 14 days of the 
treatment (by 82.0%, 79.6% and 75.3%, respectively), while distilled water decreased it by 38.8% 
and 62.3% (p = 0.0001 and p = 0.0001, respectively). Mast cell counts increased after sensitization 
by D. farinae extract (p = 0.003) and EECT attenuated the mast cell overproduction, and reduced 
mast cell degranulation markedly. Attenuation was most obvious in the early stage of EECT treat-
ment when the AD was most acute. 
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1. Introduction 
Atopic dermatitis (AD) is a chronic inflammatory skin disease accompanied by representative symptoms such as 
itch, erythema, excoriation, edema, dryness and scaling [1]. It is very prevalent in infants and nowadays has also 
spread to adolescents and adults. Its causes are not fully understood, but inflammatory dysregulation of the im-
mune system of the skin and mucous membranes in response to allergens is probably involved. This immuno-
logic disturbance is reflected in elevated serum immunoglobulin E (IgE) resulting from increased inflammatory 
cell infiltration into the skin, and is dominated by type2 helper T-cells [2]. Accordingly, AD is characterized by 
histopathologic skin changes and dermatitis lesions of the face, neck, head, arms, knees and elbows. Therefore, 
sensory evaluation of the disturbance caused by such skin lesions or determination of IgE levels is used to diag-
nose or evaluate AD [3]. 
We examined a natural material with anti-inflammatory effects as a new drug candidate for AD treatment. The 
selected natural material was extract of Cudrania tricuspidata (C. tricuspidata), a kind of mulberry tree which is 
native to East Asian countries such as Korea, China and Japan [4]-[7], and occurs mainly in the southern area of 
South Korea [5]. Extracts of the fruit, leaves, root-bark and stems of C. tricuspidata have been traditionally used 
for hepato-protection [8]-[10], and as anti-hypertension [11], anti-diabetes [12] [13], anti-allergy [14] and anti- 
oxidation [15]-[17] treatments in Korea. Well-known physiologically active compounds of C. tricuspidata are 
isoflavones and flavonoids from the fruits [18], gerontoxanthone, cudraflavone B, gericudranin, cudraxanthones, 
isocudraxanthones, some flavanones and macluraxanthone from the roots [9] [19], kaempferol and kaempferol- 
D-glucopyranoside from the leaves [20], and kaempferide-D-glucopyranoside and naringenin-D-glucopyrano- 
side from the stems [21]. However, the anti-AD effects of C. tricuspidata have not been studied except for a recent 
report using fruit extract [22]. Therefore, we examined the therapeutic effect of ethanol extract of C. tricuspidata 
stems (EECT) on AD symptoms when administered topically in an NC/Nga mice AD model induced by Derma- 
tophagoides farinae (D. farinae) extract. 
2. Materials and Methods 
2.1. Preparation of the EECT 
Dried stems of C. tricuspidata were finely powdered, and biologically active compounds were extracted with 95% 
ethanol (1:10, v/v) for 24 h, in a 60˚C water bath, then filtered through filter paper (ADVANTEC No.2, 150 mm) 
under vacuum. The filtrate was concentrated by evaporation at 45˚C, then deep-frozen at −70˚C after reconstitu-
tion in 70% ethanol in a concentration range of 100 - 200 mg/mL. The frozen filtrate was diluted appropriately 
after thawing to room temperature. Three concentrations of the ethanol extract (EECT) namely 7.5, 25 and 75 
mg/mL, were prepared by diluting with distilled water, and tested topically. 
2.2. Induction of AD-Like Skin Lesions in an NC/Nga Mouse Model 
Twenty-eight NC/Nga mice (9 week-old, male) were purchased from Central Exp. Animals Co. Ltd. (South Ko-
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rea), and all animal procedures were approved by the Institutional Animal Care and Use Committee of Hanyang 
University (No: HY-IACUC-10-062). After one-week of adaptation, the mice were anesthetized with ether and 
their heads, necks and shoulders shaved with razors and waxing cream. Then twenty-four of the mice were topi-
cally administered 100mg of D. farinae (house mite) extract-ointment (Biostar AD ointment, Japan) on their 
shaved skin regions six times over 21 days to induce AD-like skin lesions [23]. 4% SDS solution was used to 
brush their shaved skin instead of waxing cream after the first administration of house mite extract [23]. On the 
21st day, the severity of the AD-like skin lesions was evaluated. Eight mice died during the AD induction period 
during waxing and sensitization, and the remaining twenty mice were divided into five groups. 
2.3. Treatment on the AD-Like Skin Lesions with EECT 
On the 21st day EECT was administered to three experimental groups of 4 mice receiving 7.5 mg/mL, 25 mg/ml 
and 75 mg/mL EECT, respectively, for 14 days. The EECT was topically applied with a small flat brush once a 
day on all the treated skin areas. Distilled water was administered to the control group (EECT0, n = 4) in the 
same manner, while the “normal” group (normal, n = 4) received no treatment. 
2.4. Changes of AD-Like Skin Lesions 
The changes of the AD-like skin lesions were assessed visually by two trained investigators on the 21st day of 
sensitization, and after the 4th, 10th and 14th day of EECT treatment. The severity was scored as the sum of the 
AD scores for each category, namely itch, edema, erythema/hemorrhage, excoriation/erosion and dryness/ 
scaling, graded as 0 (no symptoms), 1 (mild symptoms), 2 (moderate symptoms) and 3 (severe symptoms) [24]- 
[26]. Then the AD score for each group was converted to “AD reduction (%)” calculated from the equation 
{(AD score at baseline − AD score at the 4th, 10th or 14th day of EECT treatment)/AD score at baseline} × 
100. 
2.5. Changes of Inflammation Measured from Serum IgE Levels 
Orbit blood was collected under ether anesthesia on the final day of AD induction, then on the 4th, 10th and 
14th days of treatment. Sera were deep-frozen at −70˚C after centrifugation of blood at 3000 rpm, 4˚C for 20 
min. Serum IgE levels were determined using a Mouse IgE ELISA Assay kit (XpressBio Life Science Prod-
ucts, Catalog No: 595-700, Express Biotech International, Thurmont, USA) at 450 nm expressed as {(serum 
IgE level at baseline − serum IgE level on the 4th, 10th or 14th day of EECT treatment)/serum IgE level at 
baseline} × 100. 
2.6. Histopathologic Evaluation 
After the 14 days of EECT treatment, all the mice were killed under ether anesthesia after evaluation of the 
AD-like skin lesions and orbit blood sampling, and the skin was removed from the affected regions of the ani-
mals’ heads, necks and shoulders. The skin was fixed with 10% formaldehyde, embedded in paraffin, and thin 
sections were made. The sections were stained with toluidine blue O, and microscopic examination was carried 
out at ×200; the total numbers of mast cells including granulated and degranulated forms were counted at five 
sites (400 μm2) chosen at random in each skin sample [26]-[28]. 
2.7. Statistical Evaluation 
The measurements on the five groups were compared by one-way ANOVA and by post-hoc Duncan or 
Scheffe test at p < 0.05 using SPSS ver. 21.0. Eight mice died due to excess anesthesia during the AD induc-
tion period. 
3. Results 
3.1. The Therapeutic Effects of EECT on AD-Like Skin Lesions 
The changes of AD-like skin lesions from the baseline at the end of AD induction to the 14 days after the EECT 
treatment are presented in Figure 1(a). AD-like skin lesions were reduced by the 14-day EECT treatment 
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(Figure 1(b)), and significant reductions compared to EECT 0 were noted after 4 days of treatment only with 25 
and 75 mg/mL EECT (p = 0.0001), even though EECT 7.5, 25 and 75 mg/mL were equally effective (30.1% ± 
2.4% vs. 31.4% ± 6.7% vs. 38.5% ± 2.7%). The extent of the AD reduction increased by 14 days of EECT 
treatment (63.6% ± 9.8% vs. 66.1% ± 6.3% vs. 49.6% ± 12.9%, respectively), and to a lesser extent (from 17.8%  
 
 
Figure 1. The changes of AD-like skin lesions from baseline at the end of AD induction. (a) The AD reductions (%) in each 
group were compared with the EECT0 group by one-way ANOVA with Duncan’s posthoc test. † (p < 0.001); (b) Represent-
ative photographs of AD-like skin lesions before and after EECT treatment. EECT = ethanol extract of C. tricuspidata stems; 
Normal = no AD induction and no EECT treatment; EECT0 = AD induction and distilled water treatement (control); 
EECT7.5 = AD induction and 7.5 mg/mL EECT treatment; EECT25 = AD induction and 25 mg/mL EECT treatment; 
EECT75 = AD induction and 75 mg/mL EECT treatment (mean ± SEM, n = 4).                                          
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± 5.4% (4 days) to 38.7% ± 9.9% (14 days)) in the EECT0 group. In spite of the higher AD reduction in the 
EECT-treated groups, no significant differences were found between the EECT0 and EECT-treated groups after 
14 days of EECT treatment. Importantly, the AD-like skin lesions were improved most when the mice were 
treated with EECT 25 mg/mL for 14 days, and the therapeutic effect of EECT 25 mg/mL was significantly 
greater than that seen in the EECT0 group in the early stage of treatment. 
3.2. Effects of EECT on Serum IgE Levels 
The changes of serum IgE levels during the EECT treatment for 14 days are presented in Figure 2. Serum IgE 
levels were dramatically reduced by EECT throughout the 14-day treatment, and significant reductions (%) were 
observed at each time point at 4 days (57.6% ± 7.7% vs. 65.9% ± 5.2% vs. 59.3% ± 6.7%), 10 days (74.9% ±  
5.1% vs. 80.4% ± 4.6% vs. 74.2% ± 6.7%) and 14 days (82.0% ± 3.7% vs. 79.6% ± 6.0% vs. 75.3% ± 7.4%) of 
EECT treatment (7.5 vs. 25 vs. 75 mg/mL) compared to the EECT 0 group (38.8% ± 6.9%, 53.9% ± 10.2%, and 
62.3% ± 7.5%; p = 0.0001, p = 0.0001, and p = 0.0001, respectively). EECT 7.5 and 25 mg/mL were the most 
effective doses. 
3.3. Effects on Mast Cell Counts Stained with Toluidine Blue O 
Numbers of mast cells (both granulated and degranulated forms) in the skin dermis layers stained with toluidine 
BlueO were examined by optical microscopy (200×) (Figure 3) as described in Materials and Methods. Total 
mast cell counts were significantly increased after sensitization by D. farinae extract when compared to normal 
mice (p = 0.003; (Figure 4): normal (153.0 ± 7.5) vs. EECT0 (659.0 ± 129.3), EECT7.5 (469.5 ± 39.2), 
EECT25 (541.0 ± 80.2) and EECT75 (544.0 ± 48.8)). However, total mast cell counts tended to increase less in 
 
 
Figure 2. The changes of serum IgE from baseline at the end of AD induction. The IgE reduc-
tions (%) in each group were compared with the EECT0 group by one-way ANOVA with Dun-
can’s posthoc test ‡ (p < 0.0001). EECT = ethanol extract of C. tricuspidata stems; Normal = no 
AD induction and no EECT treatment; EECT0 = AD induction and distilled water treatement 
(control); EECT7.5 = AD induction and 7.5 mg/mL EECT treatment; EECT25 = AD induction 
and 25 mg/mL EECT treatment; EECT75 = AD induction and 75 mg/mL EECT treatment (mean 
± SEM, n = 4).                                                                         
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Figure 3. The representative optical microscopic images (200×) of mast cells. Granulated (◁) and degranulated (◀) mast 
cells in the skin dermis stained with toluidine Blue O after 14 days of EECT treatment. Other details are the same as in Fig-
ure 1 and Figure 2.                                                                                       
 
 
Figure 4. Mast cell counts at five sites (400 μm2) chosen at random in the skin samples. Mean mast cell counts in each group 
were compared with the EECT0 group by one-way ANOVA with Duncan’s posthoc test, and statistical differences among 
the groups were presented as different alphabetical scripts on the bar charts of each group at p < 0.05 (mean ± SEM, n = 4). 
Other details are the same as in Figure 1 and Figure 2.                                                              
 
the EECT-treated groups, especially the EECT7.5 group, than in the distilled water-treated (EECT0) group. This 
tendency was particularly evident in the skin dermis of heads and necks. The granulated and degranulated forms 
of mast cells were also counted separately, and only the latter increased significantly after AD induction (p = 
0.0001; normal (45.0 ± 8.1) vs. EECT0 (484.8 ± 60.8)) while degranulated mast cells increased significantly less 
when treated with EECT (EECT7.5 (315.0 ± 36.6), EECT25 (289.0 ± 19.6) and EECT75 (362.0 ± 18.2)) than 
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with distilled water (Figure 4). The topical use of EECT 7.5, 25 and 75 mg/mL on the AD-like skin lesions for 
14 days was effective in reducing numbers of degranulated mast cells even though they did not reach the num-
bers in the normal group (p = 0.0001). 
4. Discussion 
In the current study, topically applied EECT had a significant effect on the severity of AD-like skin lesions, se-
rum IgE levels and on mast cell counts in the skin dermis. The anti-AD effects of EECT were detectible when 
EECT 7.5, 25 and 75 mg/mL were applied topically for 14 days to the mice (Figure 1), and these therapeutic 
effects are presumed to be due to diminution of systemic inflammatory reactions (Figure 2) and histopathologi-
cal changes (Figure 3 and Figure 4). Natural recovery from the AD-like skin lesions was also evaluated from 
the results in the EECT0 group treated with distilled water. The therapeutic efficacies of EECT 7.5, 25 and 75 
mg/mL on the AD-like skin lesions were 1.7 (30.1%), 1.8 (31.4%) and 2.2 (38.5%) times higher than that of 
EECT 0 (17.8%) after 4 days (p = 0.0001), and 1.6 (63.6%), 1.7 (66.1%) and 1.3 (49.6%) times higher than that 
of EECT 0 (38.7%) after 14 days of EECT treatment (Figure 1). The anti-inflammatory efficacies of EECT 7.5, 
25 and 75 mg/mL on serum IgE levels were also higher than those of EECT 0 (Figure 2). The anti-AD efficacy 
of EECT seemed to be more significant in the early stage (after 4 days) of EECT treatment than at the later stage 
of treatment. 
AD appears to be associated with inflammatory immune dysregulation of the skin, impaired skin barrier func-
tion, and IgE-mediated sensitization to food and environmental allergens such as microbial pathogens [29] [30]. 
Such immunologic disturbance is reflected in elevated serum IgE levels due to increased inflammatory cell in-
filtration into the skin, which is type2 helper T-cell-dominated, and, according to the immune dysregulation hy-
pothesis, the defective skin barrier is interpreted as a consequence of inflammation [2]. Regardless of how to 
explain disease progression, the acute eczematous lesions exhibit spongiosis, hyperkeratosis and parakeratosis, 
and the chronic lesions are characterized by acanthosis and perivascular infiltration of lymphocytes and mast 
cells, and by lichenification of the skin, infiltration of Th1 cells, and tissue remodeling with increased collagen 
deposition and dermal thickening [30]. From this point of view, the elevation of serum IgE levels in this NC/ 
Nga mouse AD model was related to the onset of AD-like skin lesion development [31] [32], and also similar to 
that reported in AD patients with IgE hyperproduction [33]. Therefore, topically applied EECT might be very 
effective in reducing systemic inflammatory reactions and diverse AD symptoms such as itch, edema, erythema/ 
hemorrhage, excoriation/erosion, and dryness/scaling in the early stage of AD treatment. This suggests that pa-
tients with AD could obtain relief from the severe distress of AD symptoms more easily in the very highly in-
duced AD state. 
Many skin disorders like AD seem to be related to infiltration and activation of mast cells, resulting in skin 
inflammation [30] [34]. In the current study, total mast cell counts increased significantly after 21 days of sensi-
tization (Figure 4). EECT treatment at 7.5, 25 and 75 mg/mL showed a tendency to suppress the mast cell pro-
duction in the skin dermis layers of the head, neck and shoulder of the mice. This tendency to reduce dermal 
mast cells, specially degranulated mast cells, was significant in the EECT-treated groups (p = 0.0001), when 
compared to the EECT 0 group (Figure 4). The degranulated to granulated mast cell ratio (de-G/G) was greatly 
increased after AD induction, and the de-G/G ratio was lower after EECT treatment than after treatment with 
distilled water (data not shown) though the difference was not statistically significant (p = 0.162; normal (0.4070 
± 0.042) vs. EECT0 (6.914 ± 4.062) vs. EECT7.5 (2.049 ± 0.257) vs. EECT25 (1.308 ± 0.235) vs. EECT75 
(2.1880 ± 0.357)). It has also been reported that stress-induced skin disorders due to infiltration and activation of 
mast cells in the skin dermis resulted in significant increases of granulated and degranulated mast cells in rats 
[34]-[36]. In allergic or stressed conditions, mast cells increase their IgE production [37], and degranulated 
mast cells that bind IgE increase [38] with a subsequent rise in histamine production, which generates severe 
itch and scratching of skin lesions [39]. Degranulated mast cells can initiate an acute inflammatory response 
and contribute to the progression of chronic diseases. Therefore, a decrease of mast cells, degranulated forms in 
particular, or of the deG/G ratios, in the skin is correlated with reductions of IgE and inflammatory responses, 
and could be a key to reducing the severity of AD-like skin lesions. Mast cells in the skin dermis of head and 
neck were considerably decreased by EECT 7.5, 25 and 75 mg/mL (Figure 4). This is of interest as the necks of 
AD patients were found to have higher number of mast cell profiles than any other region such as elbow, scalp 
and nates [3]. 
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The current study has a few limitations. Thus, the considerable variability of one group resulted in limited sta-
tistical power of the comparison with the other groups. It may have been caused by the small sample size of the 
groups. If the sample size had been larger, the anti-AD effect of EECT 7.5, 25 and 75 mg/mL might have been 
more significant at 14 days of EECT treatment than that of distilled water. 
In spite of the above limitation, the current study’s strengths include the fact that the EECT was applied topi-
cally to the AD-like skin lesions as an ointment. Most traditional oriental natural substances, such as mulberry 
tree extract and ginseng are orally administered. Secondly, NC/Nga mice develop AD-like skin lesions sponta-
neously under normal conditions, and they are a suitable model for some aspects of human AD, with IgE hyper-
production which is influenced by environmental factors, in part, due to interleukin-4 and -5 released by mast 
cells of the affected skin [31]. Therefore, the NC/Nga mouse model is useful for developing therapies for AD. In 
addition, it is very important to control and weaken the inflammation and dermatitis symptoms of AD, given that 
these unbearable AD symptoms are severer at night and prevalent in younger subjects. Because, AD is an in-
tractable chronic disease there should be as much focus on its control as on its complete cure. From this point of 
view, EECT may be a possible solution to reduce AD symptoms while seeking a cure for the disease. 
5. Conclusion 
Ethanol extract of C. tricuspidata stems (EECT) administered topically to an NC/Nga mouse AD model induced 
by D. farinae extract decreased serum IgE levels and degranulated mast cell counts in the dermis of the skin, and 
consequently improved the AD-like skin lesions. The anti-AD effect was especially significant when EECT 7.5 
and 25 mg/mL were applied for 14 days, and the therapeutic effect was more obvious in the early stage of EECT 
treatment when AD was strongly induced than later in the treatment. 
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